Three mega rounds show the unified thesis for 2026 funding...
By Jose Ruiz · · 7 min read
Good morning, tech and startup enthusiasts.
Jose here with your Friday briefing.
Three funding rounds landed this week that tell a complete story about where capital is flowing and what patterns are emerging. If you're hunting for the next big win, these deals show you the map.
Let's talk about what's actually happening.
Don't Buy SpaceX Stock. Buy These 3 Instead.
The biggest IPO in history is live — $1.75T valuation, $135 open, $75B raised. And history says the retail investors who chase day-one hype are the ones who get burned.
The SpaceX run created thousands of new millionaires. But it wasn't the people buying at the open. It was the ones positioned early, in the names set to ride the wave.
Our analyst pinpointed 3 stocks positioned to ride the SpaceX wave — with entry guidance and price targets, a bonus 4th pick (the most undervalued name in the sector), and a 3-phase playbook for when to buy and when to sell.
Over 2,500 investors have already read the report.
LATESTDEVELOPMENTS
FUNDRAISING |
DEAL #1: ANDURIL JUST CLOSED THE LARGEST DEFENSE TECH ROUND EVER |
The Company: Anduril Industries (Costa Mesa, CA). They build autonomous defense systems, software-defined warfare platforms, and mission-critical infrastructure for the U.S. military and allies.
The Round: Series H, $5 billion at $61 billion post-money valuation. Led by Thrive Capital and Andreessen Horowitz (a16z). Total raised to date: over $11 billion across eight rounds.
The Numbers That Matter: Revenue 2025: $2.2 billion (more than doubled YoY) Revenue trajectory: On pace for $4-5B in 2026 Contracts won YTD: $20B enterprise agreement with U.S. Army, $1.8B Air Force contract for space domain awareness Runway: Just closed $5B, so plenty of powder for expansion through profitability
What You're Actually Buying: Anduril is not just a defense contractor. They are an infrastructure play on a specific conviction about the future of warfare. CEO Brian Schimpf wrote in his investor letter that modern conflict will hinge on three things: (1) mass production of autonomous systems, (2) AI-powered coordination across those systems, and (3) the ability to manufacture and field those systems faster than adversaries can.
The Pentagon is finally writing large checks for this exact vision. $20B enterprise agreement with the Army. Spot on the Air Force's most competitive programs. Strategic position on the Collaborative Combat Aircraft (CCA) initiative, which is the Pentagon's bet-the-farm next-generation fighter program.
Anduril is building the manufacturing infrastructure (Arsenal-1, a 5M+ square foot mega factory in Ohio, plus expansions in Long Beach, CA) and the software platforms (Lattice command and control) that will sit at the center of next-generation Pentagon procurement.
Why This Round Matters: Valuation doubled in less than a year ($30.5B to $61B). For a company already at $2B+ revenue and $20B in signed contracts, that's not hype. That's institutional conviction that the defense tech category is real and Anduril is the category leader.
The fact that this round was $1B bigger than expected ($5B vs $4B rumored) signals oversubscription. Investor demand is still climbing.
The Investment Thesis: Anduril is on the path to IPO, probably 2027-2028 once business segments turn profitable. The company is already profitable on some programs, not yet on others. When that flips to company-wide profitability, IPO becomes inevitable and capital gains multiply.
At $61B private valuation, IPO target is likely $80-100B. That 30-65% upside is conservative given the category tailwinds and Pentagon procurement acceleration. Historical comparables: Palantir went public at $20B valuation, now $50B+.
For founders and operators: Anduril's playbook is clear. Win government contracts early, build manufacturing at scale, integrate vertically, expand the TAM through software platforms. Copying this works in adjacent categories (space, intelligence, logistics).
FUNDRAISING |
DEAL #2: QUEUE ROBOTICS EMERGES FROM STEALTH WITH A $670B MARKET TO ATTACK |
DEAL #2: QUEUE ROBOTICS EMERGES FROM STEALTH WITH A $670B MARKET TO ATTACK
The Company: Queue (Palo Alto, CA). They're building fully autonomous robotic pharmacy systems that fill and verify prescriptions without requiring an on-site pharmacist.
The Round: Seed, $12.6M led by AlleyCorp. Follows $6M pre-seed from Riot Ventures nine months ago. Total raised: $18.6M. Additional investors: House Capital, Ubiquity Ventures, Grep Ventures, Banter Capital.
The Market Problem: The U.S. retail pharmacy market is worth $670 billion annually. It is also structurally broken. Here's why:
Pharmacists are leaving the profession. Stores are closing. Pharmacy schools are graduating 3-4K fewer pharmacists than will be needed in the next 5-6 years. Pharmacy technician vacancy rates are 40%+ nationally. Negative reimbursements are pushing pharmacies into negative unit economics. Nearly one in three pharmacies has closed since 2010, creating pharmacy deserts in underserved areas.
The industry is in a slow-motion crisis that no incremental fix can solve.
What Queue Built: A robotic system that takes sealed wholesale pill bottles in one end and produces filled, verified prescription vials out the other. Currently supports 250 of the most-prescribed U.S. medications. Already deployed with a major national pharmacy chain as a working prototype.
Cost advantage: 96% lower cost than traditional pharmacy operations. That is not a marginal improvement. That is a structural rebirth of the unit economics.
The Founder Team: CEO Nick Desai previously founded Heal, a home healthcare company that raised $200M+. CTO Josh Liu has robotics and automation experience from Tesla and Zipline. This is not first-time founder territory. This is experienced operators solving a massive infrastructure problem.
Why This Round Matters: Oversubscribed seed from a strong syndicate. AlleyCorp rarely leads pure healthcare robotics rounds. The fact that they led signals conviction that Queue has solved a hard technical problem and identified product-market fit.
The round size (12.6M) is modest, which means Anduril-style follow-on headroom is massive. A Series A at $50M plus for this company is realistic if they hit deployment targets.
The Investment Thesis: Queue is building critical infrastructure for American healthcare. As pharmacy deserts expand and labor shortages persist, autonomous fulfillment becomes not optional but mandatory. Capital will consolidate around whoever wins this layer.
Comparable TAM models: If Queue captures even 5% of the $670B retail pharmacy market, that's a $33B+ revenue opportunity. Gross margins on robotic systems run 70-80%+ once manufacturing scales. IPO potential in 2029-2030.
For operators: This is what infrastructure looks like in healthcare. Queue is not trying to replace pharmacists. They're automating the dumb physical work (picking, counting, verifying) so pharmacists can focus on the human work (patient interaction, medication counseling, clinical decision support).
FUNDRAISING |
DEAL #3: HIGHARC RAISES $95M TO BRING AI TO HOMEBUILDING (WHERE MISTAKES ARE EXPENSIVE) |
The Company: Higharc (headquarters not fully specified in announcement, but software for homebuilding design-to-construction workflows). They build AI-powered software for the entire homebuilding lifecycle, from design through construction.
The Round: Series C, $95M led by Insight Partners. Total funding to date: $170M+.
Why This Matters:
Homebuilding is a $2+ trillion industry where labor remains stubbornly manual. Design changes ripple through construction and cost money. Inefficiencies compound across projects. Margin pressure is relentless.
Higharc is pushing AI into a workflow where mistakes are physically expensive and mathematically quantifiable. If you miscalculate a load-bearing wall dimension, that's tens of thousands in rework. If you miscommunicate a design change to site crews, that's weeks of delays.
What They're Doing:
Positioning themselves as the AI platform from design through construction. The Series C comes with major commercial expansion into new customer segments. Higharc is moving from a point solution (AI design optimization) to a platform play (AI across the entire workflow).
Why This Round Matters:
$95M Series C from Insight Partners signals institutional belief that this category is ready for scale. Insight is writing large checks into enterprise software companies with durable business models. They don't bet on thin margins or niche verticals.
The fact that this round came with major commercial expansion means existing customers are already scaling. Proof of concept has moved to real deployment.
The Investment Thesis:
Vertical AI platforms win when three conditions align: (1) the industry is large and fragmented, (2) labor is expensive and scarce, (3) mistakes are costly. Homebuilding checks all three boxes.
Higharc is not selling AI. They're selling the defragmentation of the homebuilding workflow. That's a multi-billion-dollar TAM shift.
For founders: This is the pattern to replicate. Pick a vertical where labor is 40%+ of cost, mistakes are expensive, and the workflow is still paper-based or disconnected. Build the AI platform that connects those dots. Scale by replacing the cost center with infrastructure.
PREMIUM
📰Join Founderscrowd Premium
Join Founderscrowd Premium to get:
Unique investment opportunties
Our detailed valuation analysis (why this entry point makes sense)
The specific risks to watch before IPO
How to structure your position ($25K minimum)
Real-time alerts when secondary tranches open
Step-by-step process to invest
Premium members also get first dibs on allocation — the difference between getting in and getting locked out.
$100/month. Cancel anytime. No commitment.
This is where founders and serious investors actually allocate capital.
QUICK HITS
WHAT THIS WEEK TELLS YOU
Three deals. Three different sectors. One unified thesis: Capital is consolidating around infrastructure plays in capital-intensive, mistake-sensitive, labor-shortage industries.
Anduril owns defense infrastructure. Queue owns healthcare fulfillment infrastructure. Higharc owns homebuilding workflow infrastructure.
The deals that are winning right now are not selling AI as a feature. They're selling the reengineering of expensive, broken workflows using AI as the tool.
This is where capital flows for the next 24 months. Not chatbots. Not generic AI assistants. Infrastructure that touches money, supply chains, and labor scarcity.
Hunt accordingly.
OUR FRIDAY QUESTION
Which of these three would you allocate to if you had $10M deployed today?
Send me your vote and your reasoning. jose@founderscrowds.com
The ones who think through capital allocation on a Friday are the ones making money on Monday.
Hunt accordingly. ☕
Jose
Keep reading — it's free.
Subscribe to unlock the full issue and get the next one in your inbox every morning. Already subscribed? Enter your email again.
Disclaimer: Founderscrowds is a media company. We are not a broker-dealer, funding portal, investment adviser or financial planner, and we do not collect or hold investor funds. All content is for informational and educational purposes only and is not investment, legal or tax advice or an offer to buy or sell any security. Views on any company or deal are our writers' opinions. Some content is sponsored. Private market investments are speculative, illiquid and may result in the loss of your entire investment; many offerings are limited to accredited investors. Read full disclaimer
